N/A
Completed N=20
Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Source: ClinicalTrials.gov NCT02364570 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcomePrimary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min
Summary
Cardiovascular disease (CVD) is largely a lifestyle-related condition that is the #1 killer of adults in the United States. Our work is aimed at understanding how short-term increases in blood sugar, like those that accompany eating a meal, affect blood vessel function and the risk of CVD. This research is aimed at understanding how meals composed of eggs affect short-term increases in blood sugar from eating, which are connected with increased risk of CVD. In particular, the investigators are trying to identify a specific meal composed of either whole eggs, egg yolks, or egg whites, that best reduces acute increases in blood sugar brought on by meals that consist of majority carbohydrate. At the same time, the investigators are trying to explore the protective affects that eggs may have on blood vessel function and the reduction of CVD risk.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Vascular Endothelial Function |
-294.4; -152.9; -102.9; -361.6 | — |
| SECONDARY Glucose |
461.9; 247.5; 296.1; 390.6 | — |
| SECONDARY Oxidative Stress Biomarker (Malondialdehyde; MDA) |
52.97; 16.51; 30.04; 59.2 | — |
| SECONDARY Insulin |
99433; 73970; 72645; 79235 | — |
| SECONDARY Cholecystokinin (CCK) |
-254.018; 93.659; -29.193; -150.550 | — |
| SECONDARY Methylglyoxal (MGO) |
2318.9; 1807.4; 1742.3; 2611.8 | — |
| SECONDARY 8-isoprostaglandin-F2a |
767110; 306758; 39117; 718932 | — |
| SECONDARY Arachidonic Acid (AA) |
-4771.6; -6408.8; -6109.1; -10354 | — |
| SECONDARY 8-isoprostaglandin-F2a/Arachidonic Acid |
1254.6; 435.70; 538.81; 1151.2 | — |
| SECONDARY Nitric Oxide Metabolites (Nitrites/Nitrates) (NOx) |
-1213.9; -39.71; -245.34; 607.12 | — |
| SECONDARY Arginine (Arg) |
-3645.2; -1714.4; 503.67; -1472.5 | — |
| SECONDARY Asymmetric Dimethylarginine/Arginine (ADMA/Arg) |
195.86; 59.30; -44.04; 118.62 | — |
| SECONDARY Symmetric Dimethylarginine/Arginine (SDMA/Arg) |
178.48; 62.43; -37.95; 86.03 | — |
| SECONDARY Angiotensin-II |
1223.0; 292.45; 316.19; 341.89 | — |
| SECONDARY Endothelin-I |
27.08; -13.29; -1.97; 5.59 | — |
Eligibility Criteria
Inclusion Criteria
- fasting glucose 100-125 mg/dL,
- non-dietary supplement user,
- no medications affecting vasodilation, inflammation, or energy metabolism,
- no CVD,
- nonsmokers,
- individuals having blood pressure 3 drinks/d or >10 drinks/wk), or
- ≥7 h/wk of aerobic activity.
Data sourced from ClinicalTrials.gov (NCT02364570). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.